Literature DB >> 30053966

Pleuroparenchymal fibroelastosis diagnosed by multidisciplinary discussions in Japan.

Hiroshi Ishii1, Kentaro Watanabe2, Hisako Kushima1, Tomohisa Baba3, Satoshi Watanabe4, Yoshihito Yamada5, Toru Arai6, Kenji Tsushima7, Yasuhiro Kondoh8, Yutaro Nakamura9, Yasuhiro Terasaki10, Akira Hebisawa11, Takeshi Johkoh12, Fumikazu Sakai13, Tamiko Takemura14, Yoshinori Kawabata15, Takashi Ogura3.   

Abstract

BACKGROUND: Pleuroparenchymal fibroelastosis (PPFE) is a rare subset of idiopathic interstitial pneumonias. No large-scale clinical studies of PPFE have been published. The aim of the study was to clarify the clinical and physiological characteristics of PPFE in Japan
METHODS: This was a retrospective, nationwide, and multicenter study in Japan. We reviewed 52 patients with PPFE, diagnosed after multidisciplinary discussions.
RESULTS: Flat chest index, defined as the ratio of anteroposterior diameter to transverse diameter of thoracic cage at the level of 6th thoracic vertebra, correlated positively with body mass index (BMI) (r = 0.340, p = 0.013) and percentage of predicted value of forced vital capacity (FVC %pred) (r = 0.355, p = 0.012), and negatively with the ratio of residual volume to total lung capacity (RV/TLC) (r = -0.312, p = 0.042). RV/TLC correlated negatively with BMI (r = -0.746, p < 0.0001) and FVC %pred (r = -0.507, p = 0.0005), and positively with age, and physiological variables (GAP) scores (r = 0.332, p = 0.030). The median survival time and the cumulative 5-year survival rate were 96 months and 58%, respectively. Patients with KL-6 level >600 (U/mL) survived shorter than those with <600 (p < 0.001).
CONCLUSION: Low BMI, decreased FVC and increased RV/TLC in PPFE may be related to the progression of flattened chest cage which impairs distension of chest cage at inspiration. Elevated serum levels of KL-6 suggest a poor prognosis of PPFE.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Forced vital capacity; Idiopathic pulmonary fibrosis; KL-6; Pleuroparenchymal fibroelastosis; RV/TLC

Mesh:

Substances:

Year:  2018        PMID: 30053966     DOI: 10.1016/j.rmed.2018.06.022

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  11 in total

Review 1.  Pleuroparenchymal fibroelastosis (PPFE) treated with lung transplantation and review of the literature.

Authors:  Muhammad Sajawal Ali; Vijaya Sivalingam Ramalingam; George Haasler; Kenneth Presberg
Journal:  BMJ Case Rep       Date:  2019-04-20

2.  Lung involvement during the prediagnostic phase of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Takuto Miyamura; Yoshiaki Kinoshita; Hisako Kushima; Hiroshi Mukae; Hiroshi Ishii
Journal:  ERJ Open Res       Date:  2022-05-09

Review 3.  The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Kazuki Nabeshima; Kentato Watanabe
Journal:  Histol Histopathol       Date:  2020-12-14       Impact factor: 2.303

4.  Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion.

Authors:  Tomoyuki Fujisawa; Kazutaka Mori; Masashi Mikamo; Takashi Ohno; Kensuke Kataoka; Chikatoshi Sugimoto; Hideya Kitamura; Noriyuki Enomoto; Ryoko Egashira; Hiromitsu Sumikawa; Tae Iwasawa; Shoichiro Matsushita; Hiroaki Sugiura; Mikiko Hashisako; Tomonori Tanaka; Yasuhiro Terasaki; Shinobu Kunugi; Masashi Kitani; Ryo Okuda; Yasuoki Horiike; Yasunori Enomoto; Hideki Yasui; Hironao Hozumi; Yuzo Suzuki; Yutaro Nakamura; Junya Fukuoka; Takeshi Johkoh; Yasuhiro Kondoh; Takashi Ogura; Yoshikazu Inoue; Yoshinori Hasegawa; Naohiko Inase; Sakae Homma; Takafumi Suda
Journal:  Eur Respir J       Date:  2019-05-18       Impact factor: 16.671

Review 5.  Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics.

Authors:  Felix Chua; Sujal R Desai; Andrew G Nicholson; Anand Devaraj; Elisabetta Renzoni; Alexandra Rice; Athol U Wells
Journal:  Ann Am Thorac Soc       Date:  2019-11

6.  Acute Exacerbation of Pleuroparenchymal Fibroelastosis Secondary to Allogenic Hematopoietic Stem Cell Transplantation.

Authors:  Yasushi Murakami; Koji Sakamoto; Yuki Okumura; Atsushi Suzuki; Shinji Mii; Mitsuo Sato; Toyoharu Yokoi; Naozumi Hashimoto; Yoshinori Hasegawa
Journal:  Intern Med       Date:  2020-07-14       Impact factor: 1.271

7.  Physiological Criteria Are Useful for the Diagnosis of Idiopathic Pleuroparenchymal Fibroelastosis.

Authors:  Takato Ikeda; Yoshiaki Kinoshita; Yusuke Ueda; Tomoya Sasaki; Hisako Kushima; Hiroshi Ishii
Journal:  J Clin Med       Date:  2020-11-22       Impact factor: 4.241

8.  The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis.

Authors:  Hiroshi Ishii; Yoshiaki Kinoshita; Hisako Kushima; Nobuhiko Nagata; Kentaro Watanabe
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

9.  Pleuroparenchymal fibroelastosis in Korean patients: clinico-radiologic-pathologic features and 2-year follow-up.

Authors:  Jae Ha Lee; Eun Jin Chae; Joon Seon Song; Miae Kim; Jin Woo Song
Journal:  Korean J Intern Med       Date:  2020-02-24       Impact factor: 2.884

10.  A proposed prognostic prediction score for pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Takato Ikeda; Takuto Miyamura; Yusuke Ueda; Yuji Yoshida; Hisako Kushima; Masaki Fujita; Takashi Ogura; Kentaro Watanabe; Hiroshi Ishii
Journal:  Respir Res       Date:  2021-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.